bullish

AFT Pharmaceuticals: FY23 Result — On Script

346 Views03 Jun 2023 20:00
Broker
We liked what we saw in AFT Pharmaceuticals' (AFT) FY23 result: (1) ANZ revenue (AFT's core defensive growth driver) grew +24% versus FY22, (2) underlying ROW revenue grew +71% versus FY22, and (3) 2H23 underlying gross margins were AFT's strongest ever
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Forsyth Barr
New Zealand Professional Investment Services Firm
New ZealandEquity Bottom-Up
Price Chart(Sign Up to Access)
analytics-chart
  • Loading...
x